数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
William Waddill Independent Director 62 43.70万(USD) 1.65 2020-01-28
Marianne De Backe Independent Director 51 未披露 未持股 2020-01-28
Christopher Anzalone Chief Executive Officer, President & Director 50 221.63万(USD) 236.64 2020-01-28
Mauro Ferrari Director 60 30.22万(USD) 3.97 2020-01-28
Douglass Given Chairman of the Board, Director 67 52.56万(USD) 21.01 2020-01-28
Michael S. Perry Director 60 52.29万(USD) 26.20 2020-01-28

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Patrick O’Brien General Counsel -- 155.29万(USD) 26.30 2020-01-28
Christopher Anzalone Chief Executive Officer, President & Director 50 221.63万(USD) 236.64 2020-01-28
Kenneth A. Myszkowski Chief Financial Officer -- 174.15万(USD) 40.40 2020-01-28
Bruce Given Chief Operating Officer -- 395.88万(USD) 84.17 2020-01-28

董事简历

中英对照 |  中文 |  英文
William Waddill
暂无中文简介

William Waddill began his career 30 years ago in commercial banking and public accounting and has been in the biotechnology industry for over 25 years. Since 2016 he has served on the board of Protagonist Therapeutics, a Newark, CA clinical stage biopharmaceutical company and most recently was Senior Vice President and CFO of Calithera Bioscience, a clinical stage pharmaceutical company from 2014 to 2016. Prior to Calithera, Mr. Waddill was Senior Vice President and CFO at OncoMed Pharmaceuticals from 2007 to 2014. Mr. Waddill served as the Senior Vice President and CFO of Ilypsa, Inc., a biotechnology company that was acquired in 2007 by Amgen, Inc. Before joining Ilypsa, he served as the founder and principal at Square One Finance, a financial consulting business, and Mr. Waddill served as Senior Director of Finance and Administration at Exelixis, Inc., a biotechnology company. Mr. Waddill received a BS in accounting from the University of Illinois, Chicago, and certification as a public accountant inactive after working at PriceWaterhouseCoopers and Deloitte in Boston.
暂无中文简介
William Waddill began his career 30 years ago in commercial banking and public accounting and has been in the biotechnology industry for over 25 years. Since 2016 he has served on the board of Protagonist Therapeutics, a Newark, CA clinical stage biopharmaceutical company and most recently was Senior Vice President and CFO of Calithera Bioscience, a clinical stage pharmaceutical company from 2014 to 2016. Prior to Calithera, Mr. Waddill was Senior Vice President and CFO at OncoMed Pharmaceuticals from 2007 to 2014. Mr. Waddill served as the Senior Vice President and CFO of Ilypsa, Inc., a biotechnology company that was acquired in 2007 by Amgen, Inc. Before joining Ilypsa, he served as the founder and principal at Square One Finance, a financial consulting business, and Mr. Waddill served as Senior Director of Finance and Administration at Exelixis, Inc., a biotechnology company. Mr. Waddill received a BS in accounting from the University of Illinois, Chicago, and certification as a public accountant inactive after working at PriceWaterhouseCoopers and Deloitte in Boston.
Marianne De Backe
暂无中文简介

Marianne De Backe has served as member of the Executive Committee, Executive Vice President and Head of Strategy, Business Development and Licensing of Bayer AG BAYRY Pharmaceuticals division since 2019. She is also on the board of directors of Gladstone Foundation and Ecohealth Alliance, and on the advisory board of BIOCOM Bay Area and Stanford-Bayer for Digital. From 1991 through 2019 she was at Johnson & Johnson where she most recently held global Business and Corporate Development roles including the position of Vice President of M&A Operations and Divestitures globally for the Pharmaceuticals Group and head of Infectious Diseases & Vaccines Business Development. Prior to that she led a commercial business unit in Europe as well as drug discovery research in both Europe and the United States. Dr. De Backer holds an MBA from Erasmus University Rotterdam, a Master’s degree in Molecular Biology and Biotechnology from Vrije Universiteit Brussels, and a Master’s degree in Engineering and a PhD in Biotechnology from Ghent University.
暂无中文简介
Marianne De Backe has served as member of the Executive Committee, Executive Vice President and Head of Strategy, Business Development and Licensing of Bayer AG BAYRY Pharmaceuticals division since 2019. She is also on the board of directors of Gladstone Foundation and Ecohealth Alliance, and on the advisory board of BIOCOM Bay Area and Stanford-Bayer for Digital. From 1991 through 2019 she was at Johnson & Johnson where she most recently held global Business and Corporate Development roles including the position of Vice President of M&A Operations and Divestitures globally for the Pharmaceuticals Group and head of Infectious Diseases & Vaccines Business Development. Prior to that she led a commercial business unit in Europe as well as drug discovery research in both Europe and the United States. Dr. De Backer holds an MBA from Erasmus University Rotterdam, a Master’s degree in Molecular Biology and Biotechnology from Vrije Universiteit Brussels, and a Master’s degree in Engineering and a PhD in Biotechnology from Ghent University.
Christopher Anzalone

Christopher Anzalone, 2007年12月1日,他成为公司的总裁、首席执行官及董事。2005年,Anzalone博士在Benet Group LLC公司担任首席执行官。Benet Group LLC是一家创建纳米生物科技公司的私募股权公司。在Benet集团工作期间,他是两家投资组合公司Nanotope公司(一家研究组织再生的公司)和Leonardo Biosystems公司(一家癌症药物递送公司)的创业总裁。他是Arrowhead公司全资控股子公司Arrowhead Madison 公司和多数控股子公司Calando 制药、Ablaris Therapeutics公司、Tego Biosciences公司,以及少数投资公司Leonardo Biosystems的董事。1999年至2003年,他是华盛顿特区私人股本公司Galway Partners, LLC的合伙人。他在该公司负责采购、组织和建立新企业。他是NanoInk公司(一家领先的纳米公司)的创业总裁。他在加州大学洛杉矶分校获得生物学博士学位;在劳伦斯大学获得管理学学士学位。


Christopher Anzalone has been President, Chief Executive Officer and Director of the Company since December 1 2007 and has led the Company’s business and technical development since then. Prior to joining Arrowhead, Dr. Anzalone formed and served as CEO of the Benet Group LLC, a private equity firm focused on creating and building new nano-biotechnology companies from university-generated science. Prior to his tenure at the Benet Group, from 1999 until 2003 he was a partner at the Washington, DC-based private equity firm Galway Partners, LLC, where he was responsible for sourcing, structuring and building new business ventures. Dr. Anzalone holds a PhD. in Biology from UCLA and a B.A. in Government from Lawrence University.
Christopher Anzalone, 2007年12月1日,他成为公司的总裁、首席执行官及董事。2005年,Anzalone博士在Benet Group LLC公司担任首席执行官。Benet Group LLC是一家创建纳米生物科技公司的私募股权公司。在Benet集团工作期间,他是两家投资组合公司Nanotope公司(一家研究组织再生的公司)和Leonardo Biosystems公司(一家癌症药物递送公司)的创业总裁。他是Arrowhead公司全资控股子公司Arrowhead Madison 公司和多数控股子公司Calando 制药、Ablaris Therapeutics公司、Tego Biosciences公司,以及少数投资公司Leonardo Biosystems的董事。1999年至2003年,他是华盛顿特区私人股本公司Galway Partners, LLC的合伙人。他在该公司负责采购、组织和建立新企业。他是NanoInk公司(一家领先的纳米公司)的创业总裁。他在加州大学洛杉矶分校获得生物学博士学位;在劳伦斯大学获得管理学学士学位。
Christopher Anzalone has been President, Chief Executive Officer and Director of the Company since December 1 2007 and has led the Company’s business and technical development since then. Prior to joining Arrowhead, Dr. Anzalone formed and served as CEO of the Benet Group LLC, a private equity firm focused on creating and building new nano-biotechnology companies from university-generated science. Prior to his tenure at the Benet Group, from 1999 until 2003 he was a partner at the Washington, DC-based private equity firm Galway Partners, LLC, where he was responsible for sourcing, structuring and building new business ventures. Dr. Anzalone holds a PhD. in Biology from UCLA and a B.A. in Government from Lawrence University.
Mauro Ferrari

Mauro Ferrari, 2010年被任命为Arrowhead公司的董事。 Ferrari先生是美国卫理公会医院研究所的总裁兼首席执行官。他也是纳米健康联盟的总裁。Ferrari博士是Leonardo Biosystems, Inc.公司的董事。Arrowhead公司持有该公司的少数股权。他是纳米医学和生物医学纳米技术的国际公认专家。在美国卫理公会医院研究所(TMHRI)任职之前,他是休斯顿德克萨斯大学健康科学中心的纳米医学和生物医学工程系的主席及教授。他是安德森癌症中心的实验治疗部教授、莱斯大学生物工程副教授、德克萨斯大学生物医学工程系的教授。之前,他还在加州大学伯克利分校和俄亥俄州立大学担任过教授。2003年至2005年,他是国家癌症研究所的纳米科技专家及著名学者级教授。他引领了国家癌症研究所发展部的纳米科技项目研究, 目前该项目仍然是世界纳米医学研究的最大项目。1997年以来,Ferrari博士一直是《生物医学微型设备》生物微电子机械系统和生物医学纳米技术方面的主编。Ferrari博士在纳米科技、生物科技、生物医学领域有着丰富经验,也受过以上领域的培训,因此,我们相信他完全能够胜任公司的董事。Ferrari博士受过重要的技术培训,有过一些学术经历,发表过很多文章,拥有多项专利。此外,他有几家创业公司,因此他在公司发展阶段的业务处理上有着丰富的经验。


Mauro Ferrari currently serves as Affiliate professor of Pharmaceutics at the University of Washington in Seattle, WA. He also currently serves as President of the European Research Council. From 2010 to 2019 Dr. Ferrari was President and CEO of The Houston Methodist Hospital Research Institute TMHRI, Executive Vice President of Houston Methodist Hospital and Senior Associate Dean of Weill Cornell Medical College in New York. Dr. Ferrari is an internationally recognized expert in nanomedicine and biomedical nanotechnology and Fellow, US National Academy of Inventors. Prior to assuming leadership of TMHRI, Dr. Ferrari was Professor and Chairman of The Department of NanoMedicine and Biomedical Engineering at The University of Texas Health Science Center at Houston, Professor of Experimental Therapeutics at the MD Anderson Cancer Center, Adjunct Professor of Bioengineering at Rice University and Adjunct Professor of Biomedical Engineering at the University of Texas in Austin. His previous academic appointments include tenured professorships at UC Berkeley and The Ohio State University.
Mauro Ferrari, 2010年被任命为Arrowhead公司的董事。 Ferrari先生是美国卫理公会医院研究所的总裁兼首席执行官。他也是纳米健康联盟的总裁。Ferrari博士是Leonardo Biosystems, Inc.公司的董事。Arrowhead公司持有该公司的少数股权。他是纳米医学和生物医学纳米技术的国际公认专家。在美国卫理公会医院研究所(TMHRI)任职之前,他是休斯顿德克萨斯大学健康科学中心的纳米医学和生物医学工程系的主席及教授。他是安德森癌症中心的实验治疗部教授、莱斯大学生物工程副教授、德克萨斯大学生物医学工程系的教授。之前,他还在加州大学伯克利分校和俄亥俄州立大学担任过教授。2003年至2005年,他是国家癌症研究所的纳米科技专家及著名学者级教授。他引领了国家癌症研究所发展部的纳米科技项目研究, 目前该项目仍然是世界纳米医学研究的最大项目。1997年以来,Ferrari博士一直是《生物医学微型设备》生物微电子机械系统和生物医学纳米技术方面的主编。Ferrari博士在纳米科技、生物科技、生物医学领域有着丰富经验,也受过以上领域的培训,因此,我们相信他完全能够胜任公司的董事。Ferrari博士受过重要的技术培训,有过一些学术经历,发表过很多文章,拥有多项专利。此外,他有几家创业公司,因此他在公司发展阶段的业务处理上有着丰富的经验。
Mauro Ferrari currently serves as Affiliate professor of Pharmaceutics at the University of Washington in Seattle, WA. He also currently serves as President of the European Research Council. From 2010 to 2019 Dr. Ferrari was President and CEO of The Houston Methodist Hospital Research Institute TMHRI, Executive Vice President of Houston Methodist Hospital and Senior Associate Dean of Weill Cornell Medical College in New York. Dr. Ferrari is an internationally recognized expert in nanomedicine and biomedical nanotechnology and Fellow, US National Academy of Inventors. Prior to assuming leadership of TMHRI, Dr. Ferrari was Professor and Chairman of The Department of NanoMedicine and Biomedical Engineering at The University of Texas Health Science Center at Houston, Professor of Experimental Therapeutics at the MD Anderson Cancer Center, Adjunct Professor of Bioengineering at Rice University and Adjunct Professor of Biomedical Engineering at the University of Texas in Austin. His previous academic appointments include tenured professorships at UC Berkeley and The Ohio State University.
Douglass Given

Douglass Given, 2010年11月,成为公司董事。2000年10月,他成为美国生命科学风险资本公司(Bay City Capital)的投资合伙人。他是NeoRx, Corporate Sr.公司的前任首席执行官兼董事,是万灵科(Mallinckrodt)公司的首席技术官兼副总裁,是Progenitor and Mercator Genetics公司的首席执行官兼董事。他是先灵葆雅研究所(Schering-Plough Research Institute)的副总裁;是Monsanto(孟山都公司)G.D. Searle研究实验室的副总裁;也是礼来研究实验室(Lilly research laboratories)的副总裁。Given博士是Vivaldi Biosciences生物科技公司的主席。该公司是一家私营的风险资本支持的生物科技公司。2007年至2013年, 他在芝加哥大学的普利兹克医学院的生物科学学部的访查委员会任职,并且是该委员会的终身成员及杰出校友奖的获得者。他是the Johns Hopkins Bloomberg 学校的公共卫生咨询委员会成员、是哈佛大学公共卫生部的成员、是南加州大学斯蒂文斯理工学院咨询委员会的成员。他以优异的成绩获得了芝加哥大学的硕士学位,博士学位。他还获得了宾夕法尼亚大学的沃顿商学院的工商管理硕士学位。他是哈佛大学医学院及马萨诸塞州综合医院的内科及传染病研究员。


Douglass Given is Chairman of the Board. He has been a director of the Company since 2010. Doug is Managing Partner at Health2047 Capital Partners LLC. He served as Health2047 Inc.’s Chief Executive from its founding in August 2015 until January 2018. Previously, Dr. Given spent more than a decade in venture capital as an Investment Partner and General Partner at life sciences investor Bay City Capital LLC participating in five sequential life sciences general funds and two sector-specific funds. He was associated with the partnership from 1999 to 2015. A physician and medical scientist by background, Dr. Given has been a global corporate and operating executive at Lilly, Monsanto, Schering Plough and Mallinckrodt and a serial entrepreneur, as well as a venture capitalist. In addition to a number of private companies, he led three public biotechnology and biopharmaceutical companies as CEO. Dr. Given has served on more than 20 public and private boards. He is currently a director at Health2047 Inc., board chair at Akiri Inc., Managing Partner at G5 Partners LLC, and serves on the board at First Mile Care Inc. and Vivaldi Biosciences Inc. He serves on advisory boards at the University of Chicago Medicine, Johns Hopkins Bloomberg School of Public Health, Stanford Medicine, Stanford Institute for Economic Policy Research SIEPR, and The Houston Methodist Research Institute.
Douglass Given, 2010年11月,成为公司董事。2000年10月,他成为美国生命科学风险资本公司(Bay City Capital)的投资合伙人。他是NeoRx, Corporate Sr.公司的前任首席执行官兼董事,是万灵科(Mallinckrodt)公司的首席技术官兼副总裁,是Progenitor and Mercator Genetics公司的首席执行官兼董事。他是先灵葆雅研究所(Schering-Plough Research Institute)的副总裁;是Monsanto(孟山都公司)G.D. Searle研究实验室的副总裁;也是礼来研究实验室(Lilly research laboratories)的副总裁。Given博士是Vivaldi Biosciences生物科技公司的主席。该公司是一家私营的风险资本支持的生物科技公司。2007年至2013年, 他在芝加哥大学的普利兹克医学院的生物科学学部的访查委员会任职,并且是该委员会的终身成员及杰出校友奖的获得者。他是the Johns Hopkins Bloomberg 学校的公共卫生咨询委员会成员、是哈佛大学公共卫生部的成员、是南加州大学斯蒂文斯理工学院咨询委员会的成员。他以优异的成绩获得了芝加哥大学的硕士学位,博士学位。他还获得了宾夕法尼亚大学的沃顿商学院的工商管理硕士学位。他是哈佛大学医学院及马萨诸塞州综合医院的内科及传染病研究员。
Douglass Given is Chairman of the Board. He has been a director of the Company since 2010. Doug is Managing Partner at Health2047 Capital Partners LLC. He served as Health2047 Inc.’s Chief Executive from its founding in August 2015 until January 2018. Previously, Dr. Given spent more than a decade in venture capital as an Investment Partner and General Partner at life sciences investor Bay City Capital LLC participating in five sequential life sciences general funds and two sector-specific funds. He was associated with the partnership from 1999 to 2015. A physician and medical scientist by background, Dr. Given has been a global corporate and operating executive at Lilly, Monsanto, Schering Plough and Mallinckrodt and a serial entrepreneur, as well as a venture capitalist. In addition to a number of private companies, he led three public biotechnology and biopharmaceutical companies as CEO. Dr. Given has served on more than 20 public and private boards. He is currently a director at Health2047 Inc., board chair at Akiri Inc., Managing Partner at G5 Partners LLC, and serves on the board at First Mile Care Inc. and Vivaldi Biosciences Inc. He serves on advisory boards at the University of Chicago Medicine, Johns Hopkins Bloomberg School of Public Health, Stanford Medicine, Stanford Institute for Economic Policy Research SIEPR, and The Houston Methodist Research Institute.
Michael S. Perry

Michael S. Perry, 2011年12月,加入Arrowhead公司董事会。他在诺华制药公司的干细胞疗法研究的全球总监。2005年至2012年11月,在诺华制药任职之前,他是Bay City Capital LLP公司的投资合伙人。2010年至2012年11月, 他是Poniard制药公司的首席医学官。他现任AmpliPhi Biosciences Corporation APHB.PK 公司和Avita Medical (ASX:AVH and OTCQX:AVMXY)公司的董事。2005年4月至2009年5月,他是VIA制药公司的首席开发官。该公司一家药品研发的上市公司。在那之前,2003年6月2005年4月,他是 Extropy制药公司的主席兼首席执行官。该公司是一家私营儿科专业制药公司。2002年至2003年,Perry博士担任Baxter 生物科学公司研发部门的全球总监。1997年至2000年,他是SyStemix Inc. 公司和 Genetic Therapy Inc.公司的总裁兼首席执行官。两家公司都是诺华集团的全资子公司。1994年至1997年,他是诺华制药(前身是Sandoz 制药)的法规事务的副总裁。1994年之前,他在辛泰克公司 (Syntex Corporation)、先灵葆雅公司(Schering-Plough Corporation)和BioResearch Laboratories, Inc公司担任过多个管理职务。Perry博士在加拿大安大略省圭而夫大学获得了动物医学博士学位、生物医药理学博士学位、物理学学士学位。他毕业于哈佛商学院国际管理项目系。


Michael S. Perry is currently the Chief Executive Officer and President of Avita Medical Ltd., a regenerative medicine company based in Valencia, CA ASX: AVH and OTCQX: AVMXY and Managing Director of Bioscience Managers, a global Venture Capital firm. From 2014 to 2017 Dr. Perry served as Chief Scientific Officer of Novartis’ Cell and Gene Therapy Unit, and from 2012 to 2014 he served as Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp, a US affiliate of Switzerland-based Novartis AG, a global pharmaceutical company. Dr. Perry has previously served as the Global Head of R&D at Baxter Healthcare, President and CEO of Cell & Gene Therapy at Novartis affiliates Systemix Inc. and Genetic Therapy, Inc., VP Regulatory Affairs at Sandoz Pharmaceuticals Corp. and Syntex Corp, Director of Regulatory Affairs at Schering-Plough Corporation, and Chairman, CEO or CMO at several early stage biotech companies. He also previously served as a Venture Partner with Bay City Capital, LLC, based in San Francisco, California. Dr. Perry holds a Doctor of Veterinary Medicine, a PhD in Biomedical Pharmacology, and a B.Sc. in Physics from the University of Guelph, Ontario, Canada. He is a graduate of the International Advanced Management Program at Harvard Business School.
Michael S. Perry, 2011年12月,加入Arrowhead公司董事会。他在诺华制药公司的干细胞疗法研究的全球总监。2005年至2012年11月,在诺华制药任职之前,他是Bay City Capital LLP公司的投资合伙人。2010年至2012年11月, 他是Poniard制药公司的首席医学官。他现任AmpliPhi Biosciences Corporation APHB.PK 公司和Avita Medical (ASX:AVH and OTCQX:AVMXY)公司的董事。2005年4月至2009年5月,他是VIA制药公司的首席开发官。该公司一家药品研发的上市公司。在那之前,2003年6月2005年4月,他是 Extropy制药公司的主席兼首席执行官。该公司是一家私营儿科专业制药公司。2002年至2003年,Perry博士担任Baxter 生物科学公司研发部门的全球总监。1997年至2000年,他是SyStemix Inc. 公司和 Genetic Therapy Inc.公司的总裁兼首席执行官。两家公司都是诺华集团的全资子公司。1994年至1997年,他是诺华制药(前身是Sandoz 制药)的法规事务的副总裁。1994年之前,他在辛泰克公司 (Syntex Corporation)、先灵葆雅公司(Schering-Plough Corporation)和BioResearch Laboratories, Inc公司担任过多个管理职务。Perry博士在加拿大安大略省圭而夫大学获得了动物医学博士学位、生物医药理学博士学位、物理学学士学位。他毕业于哈佛商学院国际管理项目系。
Michael S. Perry is currently the Chief Executive Officer and President of Avita Medical Ltd., a regenerative medicine company based in Valencia, CA ASX: AVH and OTCQX: AVMXY and Managing Director of Bioscience Managers, a global Venture Capital firm. From 2014 to 2017 Dr. Perry served as Chief Scientific Officer of Novartis’ Cell and Gene Therapy Unit, and from 2012 to 2014 he served as Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp, a US affiliate of Switzerland-based Novartis AG, a global pharmaceutical company. Dr. Perry has previously served as the Global Head of R&D at Baxter Healthcare, President and CEO of Cell & Gene Therapy at Novartis affiliates Systemix Inc. and Genetic Therapy, Inc., VP Regulatory Affairs at Sandoz Pharmaceuticals Corp. and Syntex Corp, Director of Regulatory Affairs at Schering-Plough Corporation, and Chairman, CEO or CMO at several early stage biotech companies. He also previously served as a Venture Partner with Bay City Capital, LLC, based in San Francisco, California. Dr. Perry holds a Doctor of Veterinary Medicine, a PhD in Biomedical Pharmacology, and a B.Sc. in Physics from the University of Guelph, Ontario, Canada. He is a graduate of the International Advanced Management Program at Harvard Business School.

高管简历

中英对照 |  中文 |  英文
Patrick O’Brien

Patrick O’Brien 是总法律顾问,于2014年12月加入本公司。O’Brien先生在医疗保健法律领域开展法律执业超过20年.加入该公司以前,从2012年到2014年,O’Brien先生在Shire任职,他在该公司担任法律部的事业部副总裁。在Shire工作前,他担任国际律师事务所Holland & Knight LLP华盛顿特区办事处的合伙人。O’Brien先生于2010年与人合作创始律所O’Brien Gould PLLC,该公司于2011年与Holland & Knight合并。从2009年至2010年,O’Brien先生是 Burke O’Neil LLC的合伙人。从2001年到2009年,O’Brien先生担任强生公司(Johnson & Johnson)的几个法律职位,包括担任J&J&’s Centocor 奥托生物技术单位的法律部副总裁。在这之前,O’Brien先生担任美国食品药品监督管理局(United States Food & Drug Administration)的监管法律顾问。O’Brien先生在亚利桑那大学(University of Arizona)被授予药学理学学士学位和药学博士学位,之后在伊利诺伊大学(University of Illinois)芝加哥医院(Chicago Hospital)完成临床药学住院医师实习。他还在亚利桑那大学(University of Arizona)被授予法学博士学位。


Patrick O’Brien joined the Company in December 2014. Mr. O’Brien has practiced in the healthcare legal field for over 20 years. Before joining the Company, from 2012 to 2014 Mr. O’Brien was with Shire, where he was Group Vice President, Law. Immediately prior to working with Shire he was a partner with the international law firm of Holland & Knight LLP in its Washington, DC office. In 2010 Mr. O’Brien co-founded the law firm O’Brien Gould PLLC which joined Holland & Knight in 2011. From 2009 - 2010 Mr. O’Brien was a partner in Burke O’Neil LLC. From 2001 - 2009 Mr. O’Brien served in several legal roles with Johnson & Johnson, including serving as Vice President of Law for J&J’s Centocor Ortho-Biotech unit. Mr. O’Brien previously served as Regulatory Counsel with the United States Food & Drug Administration. Mr. O’Brien was awarded a BS in Pharmacy and a PharmD from the University of Arizona before completing a residency in Clinical Pharmacy with the University of Illinois at Chicago Hospital. He was also awarded his JD from the University of Arizona.
Patrick O’Brien 是总法律顾问,于2014年12月加入本公司。O’Brien先生在医疗保健法律领域开展法律执业超过20年.加入该公司以前,从2012年到2014年,O’Brien先生在Shire任职,他在该公司担任法律部的事业部副总裁。在Shire工作前,他担任国际律师事务所Holland & Knight LLP华盛顿特区办事处的合伙人。O’Brien先生于2010年与人合作创始律所O’Brien Gould PLLC,该公司于2011年与Holland & Knight合并。从2009年至2010年,O’Brien先生是 Burke O’Neil LLC的合伙人。从2001年到2009年,O’Brien先生担任强生公司(Johnson & Johnson)的几个法律职位,包括担任J&J&’s Centocor 奥托生物技术单位的法律部副总裁。在这之前,O’Brien先生担任美国食品药品监督管理局(United States Food & Drug Administration)的监管法律顾问。O’Brien先生在亚利桑那大学(University of Arizona)被授予药学理学学士学位和药学博士学位,之后在伊利诺伊大学(University of Illinois)芝加哥医院(Chicago Hospital)完成临床药学住院医师实习。他还在亚利桑那大学(University of Arizona)被授予法学博士学位。
Patrick O’Brien joined the Company in December 2014. Mr. O’Brien has practiced in the healthcare legal field for over 20 years. Before joining the Company, from 2012 to 2014 Mr. O’Brien was with Shire, where he was Group Vice President, Law. Immediately prior to working with Shire he was a partner with the international law firm of Holland & Knight LLP in its Washington, DC office. In 2010 Mr. O’Brien co-founded the law firm O’Brien Gould PLLC which joined Holland & Knight in 2011. From 2009 - 2010 Mr. O’Brien was a partner in Burke O’Neil LLC. From 2001 - 2009 Mr. O’Brien served in several legal roles with Johnson & Johnson, including serving as Vice President of Law for J&J’s Centocor Ortho-Biotech unit. Mr. O’Brien previously served as Regulatory Counsel with the United States Food & Drug Administration. Mr. O’Brien was awarded a BS in Pharmacy and a PharmD from the University of Arizona before completing a residency in Clinical Pharmacy with the University of Illinois at Chicago Hospital. He was also awarded his JD from the University of Arizona.
Christopher Anzalone

Christopher Anzalone, 2007年12月1日,他成为公司的总裁、首席执行官及董事。2005年,Anzalone博士在Benet Group LLC公司担任首席执行官。Benet Group LLC是一家创建纳米生物科技公司的私募股权公司。在Benet集团工作期间,他是两家投资组合公司Nanotope公司(一家研究组织再生的公司)和Leonardo Biosystems公司(一家癌症药物递送公司)的创业总裁。他是Arrowhead公司全资控股子公司Arrowhead Madison 公司和多数控股子公司Calando 制药、Ablaris Therapeutics公司、Tego Biosciences公司,以及少数投资公司Leonardo Biosystems的董事。1999年至2003年,他是华盛顿特区私人股本公司Galway Partners, LLC的合伙人。他在该公司负责采购、组织和建立新企业。他是NanoInk公司(一家领先的纳米公司)的创业总裁。他在加州大学洛杉矶分校获得生物学博士学位;在劳伦斯大学获得管理学学士学位。


Christopher Anzalone has been President, Chief Executive Officer and Director of the Company since December 1 2007 and has led the Company’s business and technical development since then. Prior to joining Arrowhead, Dr. Anzalone formed and served as CEO of the Benet Group LLC, a private equity firm focused on creating and building new nano-biotechnology companies from university-generated science. Prior to his tenure at the Benet Group, from 1999 until 2003 he was a partner at the Washington, DC-based private equity firm Galway Partners, LLC, where he was responsible for sourcing, structuring and building new business ventures. Dr. Anzalone holds a PhD. in Biology from UCLA and a B.A. in Government from Lawrence University.
Christopher Anzalone, 2007年12月1日,他成为公司的总裁、首席执行官及董事。2005年,Anzalone博士在Benet Group LLC公司担任首席执行官。Benet Group LLC是一家创建纳米生物科技公司的私募股权公司。在Benet集团工作期间,他是两家投资组合公司Nanotope公司(一家研究组织再生的公司)和Leonardo Biosystems公司(一家癌症药物递送公司)的创业总裁。他是Arrowhead公司全资控股子公司Arrowhead Madison 公司和多数控股子公司Calando 制药、Ablaris Therapeutics公司、Tego Biosciences公司,以及少数投资公司Leonardo Biosystems的董事。1999年至2003年,他是华盛顿特区私人股本公司Galway Partners, LLC的合伙人。他在该公司负责采购、组织和建立新企业。他是NanoInk公司(一家领先的纳米公司)的创业总裁。他在加州大学洛杉矶分校获得生物学博士学位;在劳伦斯大学获得管理学学士学位。
Christopher Anzalone has been President, Chief Executive Officer and Director of the Company since December 1 2007 and has led the Company’s business and technical development since then. Prior to joining Arrowhead, Dr. Anzalone formed and served as CEO of the Benet Group LLC, a private equity firm focused on creating and building new nano-biotechnology companies from university-generated science. Prior to his tenure at the Benet Group, from 1999 until 2003 he was a partner at the Washington, DC-based private equity firm Galway Partners, LLC, where he was responsible for sourcing, structuring and building new business ventures. Dr. Anzalone holds a PhD. in Biology from UCLA and a B.A. in Government from Lawrence University.
Kenneth A. Myszkowski

Kenneth A. Myszkowski, 2009年加入Arrowhead公司,担任该公司的首席财务官。加入Arrowhead公司之前,他是Broadwind Energy公司的财务总监。Broadwind Energy公司是一家为风力发电产业提供商产品及服务的上市公司。在Broadwind Energy公司任职之前,他是Epcor USA公司的Epcor Utilities, Inc美国总部的财务总监。该公司是一家能源上市公司。加入Epcor之前,他是两个初创企业NanoInk,公司(专门从事纳米蘸水笔技术和纳米组装技术研发的公司)和Delphion公司(为知识产权研究提供在线工具的公司)的财务总监。Myszkowski先生在FMC Corporation(美国富美实公司及Premark International公司的担任过多种职务,两家公司均是财富500强企业。他在伊利诺斯州芝加哥市的Arthur Andersen & Co公司审计实务开始他的职业生涯。他在伊利诺斯大学获得了本科学士学位,在芝加哥大学布斯商学院获得了工商管理硕士。他是一名注册公共会计师。


Kenneth A. Myszkowski joined Arrowhead in 2009. Prior to joining Arrowhead, Mr. Myszkowski served as the corporate controller for Broadwind Energy, a public energy company which provides products and services to the wind energy industry. Previous to his position at Broadwind, Mr. Myszkowski was controller for Epcor USA, the U.S. headquarters for Epcor Utilities, Inc., a public energy company. Prior to Epcor, Mr. Myszkowski was controller for two start-up ventures: NanoInk, specializing in Dip Pen Nanolithography, a nanofabrication technology, and Delphion, which provided on-line tools for intellectual property research. Mr. Myszkowski also held several corporate roles at FMC Corporation and Premark International, both Fortune 500 conglomerates. He began his career in the audit practice of Arthur Andersen & Co. in Chicago, Illinois. Mr. Myszkowski received his undergraduate degree from the University of Illinois, and his MBA from the University of Chicago Booth School of Business. He is a certified public accountant.
Kenneth A. Myszkowski, 2009年加入Arrowhead公司,担任该公司的首席财务官。加入Arrowhead公司之前,他是Broadwind Energy公司的财务总监。Broadwind Energy公司是一家为风力发电产业提供商产品及服务的上市公司。在Broadwind Energy公司任职之前,他是Epcor USA公司的Epcor Utilities, Inc美国总部的财务总监。该公司是一家能源上市公司。加入Epcor之前,他是两个初创企业NanoInk,公司(专门从事纳米蘸水笔技术和纳米组装技术研发的公司)和Delphion公司(为知识产权研究提供在线工具的公司)的财务总监。Myszkowski先生在FMC Corporation(美国富美实公司及Premark International公司的担任过多种职务,两家公司均是财富500强企业。他在伊利诺斯州芝加哥市的Arthur Andersen & Co公司审计实务开始他的职业生涯。他在伊利诺斯大学获得了本科学士学位,在芝加哥大学布斯商学院获得了工商管理硕士。他是一名注册公共会计师。
Kenneth A. Myszkowski joined Arrowhead in 2009. Prior to joining Arrowhead, Mr. Myszkowski served as the corporate controller for Broadwind Energy, a public energy company which provides products and services to the wind energy industry. Previous to his position at Broadwind, Mr. Myszkowski was controller for Epcor USA, the U.S. headquarters for Epcor Utilities, Inc., a public energy company. Prior to Epcor, Mr. Myszkowski was controller for two start-up ventures: NanoInk, specializing in Dip Pen Nanolithography, a nanofabrication technology, and Delphion, which provided on-line tools for intellectual property research. Mr. Myszkowski also held several corporate roles at FMC Corporation and Premark International, both Fortune 500 conglomerates. He began his career in the audit practice of Arthur Andersen & Co. in Chicago, Illinois. Mr. Myszkowski received his undergraduate degree from the University of Illinois, and his MBA from the University of Chicago Booth School of Business. He is a certified public accountant.
Bruce Given

Bruce Given, 2011年加入Arrowhead公司,担任该公司的首席运营官。2009年10月1日以来,Given博士担任了该公司的子公司Calando Pharmaceuticals, Inc.公司的董事。2010年2月1日,他担任了Leonardo Biosystems, Inc.公司的首席执行官。Arrowhead公司持有该公司的少量股权 从2004年起直到2013年他退休,他一直是ICON, plc.公司的董事会成员。2010年至2013年,他是该公司的董事会主席。2002年至2007年,他是恩赛斯夫制药(Encysive Pharmaceuticals)公司的总裁、首席执行官,以及董事。恩赛斯夫制药(Encysive Pharmaceuticals)公司是一家商业制药研发公司。到2011年,他在恩赛斯夫制药公司的任期结束后,他担任了Bruce Given Consulting咨询公司的总裁。Bruce Given Consulting是一家为生物科技公司提供咨询服务的公司。在恩赛斯夫制药公司任职之前,他在Johnson and Johnson公司、Sandoz 制药公司、以及Schering-Plough公司担任过多则行政职务。他在科罗拉多州立大学获得科学学士学位,他曾是该大学优等生荣誉学会的成员。他在芝加哥大学的普利兹克医学院获得了硕士学位。他在芝加哥大学和波士顿布莱根妇女医院完成了他的医疗培训。在医疗培训期间,他还是哈佛医学院的临床研究员。他在内科医学、内分泌学、新陈代谢学等方面获得专业认证。他撰写了33本科学书籍。Bruce Given博士与Douglass Given博士是兄弟。Douglass Given博士也是公司的董事。


Bruce Given joined Arrowhead in 2011. Dr. Given was a member of the Board of Directors for ICON, plc. from 2004 until his retirement in 2013 and Chairman of its Board of Directors from 2010 to 2013. Dr. Given served as the President and Chief Executive Officer, and as a member of the Board of Directors of Encysive Pharmaceuticals, an R&D-based commercial pharmaceutical company, roles he held from 2002 through 2007. Subsequent to his tenure at Encysive until 2011 Dr. Given was President of Bruce Given Consulting, a firm that provides consulting services to biotech companies. Since October 1 2009 Dr. Given has been a director of Calando Pharmaceuticals, Inc., and from February 2010 until its dissolution in October 2014 Dr. Given was the Chief Executive Officer of Leonardo Biosystems, Inc., in which Arrowhead held a minority equity interest. Prior to his tenure at Encysive, Dr. Given held several senior executive roles at Johnson and Johnson, Sandoz Pharmaceuticals and Schering-Plough. Dr. Given obtained his bachelor of sciences degree from Colorado State University, graduating Phi Beta Kappa. He received his M.D. degree with honors from the University of Chicago, Pritzker School of Medicine and completed his medical training at the University of Chicago and at Brigham and Women’s Hospital in Boston, where he was a Clinical Fellow at Harvard Medical School. He is board certified in internal medicine and endocrinology and metabolism and has authored 33 scientific publications. Dr. Bruce Given is a brother of Dr. Douglass Given, a director of the company.
Bruce Given, 2011年加入Arrowhead公司,担任该公司的首席运营官。2009年10月1日以来,Given博士担任了该公司的子公司Calando Pharmaceuticals, Inc.公司的董事。2010年2月1日,他担任了Leonardo Biosystems, Inc.公司的首席执行官。Arrowhead公司持有该公司的少量股权 从2004年起直到2013年他退休,他一直是ICON, plc.公司的董事会成员。2010年至2013年,他是该公司的董事会主席。2002年至2007年,他是恩赛斯夫制药(Encysive Pharmaceuticals)公司的总裁、首席执行官,以及董事。恩赛斯夫制药(Encysive Pharmaceuticals)公司是一家商业制药研发公司。到2011年,他在恩赛斯夫制药公司的任期结束后,他担任了Bruce Given Consulting咨询公司的总裁。Bruce Given Consulting是一家为生物科技公司提供咨询服务的公司。在恩赛斯夫制药公司任职之前,他在Johnson and Johnson公司、Sandoz 制药公司、以及Schering-Plough公司担任过多则行政职务。他在科罗拉多州立大学获得科学学士学位,他曾是该大学优等生荣誉学会的成员。他在芝加哥大学的普利兹克医学院获得了硕士学位。他在芝加哥大学和波士顿布莱根妇女医院完成了他的医疗培训。在医疗培训期间,他还是哈佛医学院的临床研究员。他在内科医学、内分泌学、新陈代谢学等方面获得专业认证。他撰写了33本科学书籍。Bruce Given博士与Douglass Given博士是兄弟。Douglass Given博士也是公司的董事。
Bruce Given joined Arrowhead in 2011. Dr. Given was a member of the Board of Directors for ICON, plc. from 2004 until his retirement in 2013 and Chairman of its Board of Directors from 2010 to 2013. Dr. Given served as the President and Chief Executive Officer, and as a member of the Board of Directors of Encysive Pharmaceuticals, an R&D-based commercial pharmaceutical company, roles he held from 2002 through 2007. Subsequent to his tenure at Encysive until 2011 Dr. Given was President of Bruce Given Consulting, a firm that provides consulting services to biotech companies. Since October 1 2009 Dr. Given has been a director of Calando Pharmaceuticals, Inc., and from February 2010 until its dissolution in October 2014 Dr. Given was the Chief Executive Officer of Leonardo Biosystems, Inc., in which Arrowhead held a minority equity interest. Prior to his tenure at Encysive, Dr. Given held several senior executive roles at Johnson and Johnson, Sandoz Pharmaceuticals and Schering-Plough. Dr. Given obtained his bachelor of sciences degree from Colorado State University, graduating Phi Beta Kappa. He received his M.D. degree with honors from the University of Chicago, Pritzker School of Medicine and completed his medical training at the University of Chicago and at Brigham and Women’s Hospital in Boston, where he was a Clinical Fellow at Harvard Medical School. He is board certified in internal medicine and endocrinology and metabolism and has authored 33 scientific publications. Dr. Bruce Given is a brother of Dr. Douglass Given, a director of the company.